Loading stock data…
AtriCure, Inc. (ATRC)
$53.73+2.21 (+4.29%)
Market ClosedLast close Sep 8
AtriCure, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AtriCure, Inc. in the Healthcare sector is trading at $53.73 with a market capitalization of $2.5B. Wall Street consensus targets $51.67 (9 analysts), implying a -3.8% move over the next 12 months. The stock is currently near its 52-week high of $55.72, remaining 55.2% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $153.60M↑ | $141.25M↑ | $140.50M↑ | $134.27M↓ | $136.14M |
| Gross Profit | $118.63M↑ | $109.31M↑ | $105.34M↑ | $101.33M↓ | $101.48M |
| Operating Income | $9.66M↑ | $526,000↓ | $2.49M↑ | $208,000↑ | -$6.19M |
| Net Income | $8.96M↑ | $108,000↓ | $1.76M↑ | -$267,000↑ | -$6.19M |
Peer Comparison
JNJUNHPFE
Fundamentals
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.47B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
231.14
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.23
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
2.04%
Volume
Today's trading volume
1.85M
Recent News
Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?
Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth
AtriCure (NASDAQ:ATRC) said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoption, expanding procedure volumes and progress in clinical trials. Speaking at the Canaccord Genuity G
Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors
The sale came at $38.42 per share, slightly below the day's market close, as AtriCure maintains its $2.0 billion market cap in the medical device sector.
An AtriCure Director Sold $905,000 in Stock. Here's How to Read It
Prange's open-market disposition reduced her direct holdings by 14%, though she retains over 22,800 shares in the $2.0 billion medical device company.
Project Horizon and Outlook Upgrade Might Change The Case For Investing In Inspire Medical Systems (INSP)
Inspire Medical Systems recently appointed AtriCure CEO Michael H. Carrel to its Board and committees, while long-serving director Casey M. Tansey plans to retire, as the company reported quarterly revenue of US$200.58 million and earnings of US$0.14 per share that exceeded analyst expectations despite a year-on-year decline. Alongside these governance changes, Inspire raised its full-year outlook and launched Project Horizon, aimed at unlocking US$30 million in annualized investment...